61 related articles for article (PubMed ID: 15957612)
41. Comparison of deferoxamine pharmacokinetics between asymptomatic thalassemic children and those exhibiting severe neurotoxicity.
Bentur Y; Koren G; Tesoro A; Carley H; Olivieri N; Freedman MH
Clin Pharmacol Ther; 1990 Apr; 47(4):478-82. PubMed ID: 2328556
[TBL] [Abstract][Full Text] [Related]
42. Ocular and auditory toxicity in hemodialyzed patients receiving desferrioxamine.
Cases A; Kelly J; Sabater F; Torras A; Griño MC; Lopez-Pedret J; Revert L
Nephron; 1990; 56(1):19-23. PubMed ID: 2234245
[TBL] [Abstract][Full Text] [Related]
43. Acute visual disorders in patients on regular dialysis given desferrioxamine as a test.
Ravelli M; Scaroni P; Mombelloni S; Movilli E; Feller P; Apostoli P; De Maria G; Valotti C; Sciuto G; Maiorca R
Nephrol Dial Transplant; 1990; 5(11):945-9. PubMed ID: 2127831
[TBL] [Abstract][Full Text] [Related]
44. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
Kontoghiorghe CN; Kontoghiorghes GJ
Drug Des Devel Ther; 2016; 10():465-81. PubMed ID: 26893541
[TBL] [Abstract][Full Text] [Related]
45. The electrooculogram.
Creel DJ
Handb Clin Neurol; 2019; 160():495-499. PubMed ID: 31277871
[TBL] [Abstract][Full Text] [Related]
46. Retinal abnormalities in β-thalassemia major.
Bhoiwala DL; Dunaief JL
Surv Ophthalmol; 2016; 61(1):33-50. PubMed ID: 26325202
[TBL] [Abstract][Full Text] [Related]
47. [Retinal dysfunction in patients treated with vigabatrin].
Podboraczyńska-Jodkoi K; Lubiński W; Hampel-Osipowicz E
Klin Oczna; 2007; 109(1-3):85-8. PubMed ID: 17687922
[TBL] [Abstract][Full Text] [Related]
48. Efficacy and safety of iron chelators in thalassemia and sickle cell disease: a multiple treatment comparison network meta-analysis and trial sequential analysis.
Sridharan K; Sivaramakrishnan G
Expert Rev Clin Pharmacol; 2018 Jun; 11(6):641-650. PubMed ID: 29727586
[TBL] [Abstract][Full Text] [Related]
49. Recent developments in iron chelation therapy.
Cario H; Janka-Schaub G; Janssen G; Jarisch A; Strauss G; Kohne E
Klin Padiatr; 2007; 219(3):158-65. PubMed ID: 17525910
[TBL] [Abstract][Full Text] [Related]
50. The use of chelating agents in the treatment of aluminum overload.
Domingo JL
J Toxicol Clin Toxicol; 1989; 27(6):355-67. PubMed ID: 2697761
[TBL] [Abstract][Full Text] [Related]
51. The toxic effects of desferrioxamine.
Porter JB; Huehns ER
Baillieres Clin Haematol; 1989 Apr; 2(2):459-74. PubMed ID: 2660937
[TBL] [Abstract][Full Text] [Related]
52. Medications and retinal toxicity.
Schwartz SG; Mieler WF
Ophthalmol Clin North Am; 2002 Dec; 15(4):517-28. PubMed ID: 12515084
[TBL] [Abstract][Full Text] [Related]
53. EOG as a monitor of desferrioxamine retinal toxicity.
Hidajat RR; McLay JL; Goode DH; Spearing RL
Doc Ophthalmol; 2004 Nov; 109(3):273-8. PubMed ID: 15957612
[TBL] [Abstract][Full Text] [Related]
54. Functional and Structural Abnormalities in Deferoxamine Retinopathy: A Review of the Literature.
Di Nicola M; Barteselli G; Dell'Arti L; Ratiglia R; Viola F
Biomed Res Int; 2015; 2015():249617. PubMed ID: 26167477
[TBL] [Abstract][Full Text] [Related]
55. [Retinopathy caused by interferon alpha associated with ribavirin therapy and the importance of the electro-oculogram: a case report].
Crochet M; Ingster-Moati I; Even G; Dupuy P
J Fr Ophtalmol; 2004 Mar; 27(3):257-62. PubMed ID: 15039627
[TBL] [Abstract][Full Text] [Related]
56. Alström syndrome--a case report and literature review.
Karska-Basta I; Kubicka-Trzaska A; Filemonowicz-Skoczek A; Romanowska-Dixon B; Kobylarz J
Klin Oczna; 2008; 110(4-6):188-92. PubMed ID: 18655459
[TBL] [Abstract][Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
